About Furiex Pharmaceuticals (NASDAQ:FURX)
Furiex Pharmaceuticals, Inc. is a drug development collaboration company. The Company's product pipeline includes two marketed products and three programs in development, including late-stage compounds, in multiple therapeutic areas. Its programs include Priligy, Alogliptin Nesina, Alogliptin/Actose Combination, Alogliptin/Metformin Combination, Fluoroquinolone, Mu Delta and PPD 10558. In November 2011, it acquired full exclusive license rights to develop and commercialize the compound MuDelta under its existing development and license agreement with Janssen Pharmaceutica N.V. Effective July 2, 2014 Forest Laboratories Inc, a unit of Actavis PLC, acquired the entire share capital of Furiex Pharmaceuticals Inc.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Life Sciences Tools & Services
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:FURX
- CUSIP: 36106P10
- Web: N/A
- Trailing P/E Ratio:
- Foreward P/E Ratio: 99.78
- P/E Growth:
Frequently Asked Questions for Furiex Pharmaceuticals (NASDAQ:FURX)
What is Furiex Pharmaceuticals' stock symbol?
Furiex Pharmaceuticals trades on the NASDAQ under the ticker symbol "FURX."
Who are some of Furiex Pharmaceuticals' key competitors?
Some companies that are related to Furiex Pharmaceuticals include Partnership Assurance Group PLC (PA), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Hospira (HSP), Smith & Nephew plc (SN), Omnicare (OCR), VCA (WOOF), NMC Health PLC (NMC), Valeant Pharmaceuticals Intl (VRX), Catalent (CTLT), PRA Health Sciences (PRAH), Health Net (HNT), Patheon NV (PTHN), Mediclinic International PLC (MDC), Puma Biotechnology (PBYI), Taro Pharmaceutical Industries (TARO) and ConvaTec Group PLC (CTEC).
How do I buy Furiex Pharmaceuticals stock?
Shares of Furiex Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Furiex Pharmaceuticals' stock price today?
MarketBeat Community Rating for Furiex Pharmaceuticals (NASDAQ FURX)MarketBeat's community ratings are surveys of what our community members think about Furiex Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Furiex Pharmaceuticals stock can currently be purchased for approximately $104.77.
Consensus Ratings for Furiex Pharmaceuticals (NASDAQ:FURX) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for Furiex Pharmaceuticals (NASDAQ:FURX)
Analysts' Ratings History for Furiex Pharmaceuticals (NASDAQ:FURX)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Furiex Pharmaceuticals (NASDAQ:FURX)Earnings History by Quarter for Furiex Pharmaceuticals (NASDAQ FURX)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/7/2014||Q114||($0.63)||($1.25)||$10.01 million||$6.40 million||View||N/A|
|3/11/2014||Q413||($1.06)||($0.63)||$12.80 million||$13.10 million||View||N/A|
|8/6/2013||Q2 2013||($1.65)||($2.32)||$11.94 million||$3.00 million||View||N/A|
|5/7/2013||Q1 2013||$0.70||$0.82||$33.42 million||$39.33 million||View||N/A|
|3/6/2013||Q4 2012||($2.04)||($0.90)||$7.43 million||$9.21 billion||View||N/A|
Earnings Estimates for Furiex Pharmaceuticals (NASDAQ:FURX)
Current Year EPS Consensus Estimate: $-2.27 EPS
Next Year EPS Consensus Estimate: $1.05 EPS
Dividend History for Furiex Pharmaceuticals (NASDAQ:FURX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Furiex Pharmaceuticals (NASDAQ:FURX)Insider Trades by Quarter for Furiex Pharmaceuticals (NASDAQ:FURX)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|6/24/2014||Paul S Covington||VP||Sell||10,368||$104.12||$1,079,516.16|| |
|6/24/2014||Sailash Patel||CFO||Sell||32,928||$104.00||$3,424,512.00|| |
|6/18/2014||Paul S Covington||VP||Sell||45,691||$104.11||$4,756,890.01|| |
|6/17/2014||Gail Frances Mcintyre||SVP||Sell||74,457||$105.01||$7,818,729.57|| |
|6/13/2014||Paul S Covington||VP||Sell||3,228||$104.25||$336,519.00|| |
|6/10/2014||Gail Frances Mcintyre||SVP||Sell||1,746||$104.58||$182,596.68|| |
|6/10/2014||Paul S Covington||VP||Sell||2,872||$104.63||$300,497.36|| |
|6/10/2014||Sailash Patel||CFO||Sell||1,504||$104.68||$157,438.72|| |
|9/10/2013||Paul S Covington||VP||Sell||30,000||$40.89||$1,226,700.00|| |
|8/9/2013||Peter Corr||Director||Sell||7,500||$39.74||$298,050.00|| |
|7/19/2013||Gail Frances Mcintyre||SVP||Sell||10,581||$40.00||$423,240.00|| |
|3/12/2013||Stephen W Kaldor||Director||Sell||6,352||$41.58||$264,116.16|| |
|8/15/2012||June Sherie Almenoff||President||Buy||1,000||$18.67||$18,670.00|| |
Headline Trends for Furiex Pharmaceuticals (NASDAQ:FURX)
Latest Headlines for Furiex Pharmaceuticals (NASDAQ:FURX)
No headlines for this company have been tracked by MarketBeat.com
Furiex Pharmaceuticals (FURX) Chart for Tuesday, October, 17, 2017